Background: Ligneous conjunctivitis is a very rare form of pseudomembranous conjunctivitis with few published cases in literature. We aim to describe the ocular findings and treatment in an infant with ligneous conjunctivitis resembling preseptal cellulitis on presentation.
Materials And Methods: Case report of a 3-month-old girl who was referred to a tertiary centre for ophthalmic assessment due to progressive eyelid oedema with no response to initiated topical and systemic antibiotics. Ethical approval has been achieved from the local ethics committee of the Ghent University Hospital and informed consent has been obtained from the parents of the child.
Results: Examination under general anaesthesia showed multiple, wood-like fibrinous pseudomembranes, originating from the conjunctiva, consistent with ligneous conjunctivitis. After careful removal of the coagulated exudate covering the cornea, a central corneal epithelial defect was evident without stromal infiltration. Histopathologic examination confirmed the predominance of fibrin within the pseudomembranes. Plasminogen activity was below the normal range. Genetic analysis did not identify a pathogenic variant in the PLG gene. The corneal epithelium re-epithelialised during the following days and the conjunctival lesions gradually subsided over the ensuing weeks whilst continuing heparin-containing artificial tears.
Conclusion: A high level of suspicion is warranted in atypical cases of preseptal cellulitis which show no response to antibiotic treatment. Particularly in young children, examination under general anesthesia is warranted to allow diagnosis of rare causes of secondary eyelid oedema. We report an infant with unilateral ligneous conjunctivitis who responded well to topical, commercially-available heparin-containing artificial tears treatment. This approach is an effective and easy first-line treatment option in this condition, particularly in milder phenotypes.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1080/13816810.2022.2092756 | DOI Listing |
Orbit
November 2024
Corneoplastic Unit, Queen Victoria Hospital NHS Foundation Trust, East Grinstead, UK.
Spec Care Dentist
December 2024
Department of Pathology and Oral Diagnosis, School of Dentistry, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil.
SAGE Open Med Case Rep
July 2024
Department of Neurosurgery, Istishari Arab Hospital, Ramallah, Palestine.
Type I plasminogen (PLG I) deficiency is a genetic disorder inherited in an autosomal recessive mode and carries high mortality and morbidity. This case report discusses two babies, aged 2 and 3 months, who were diagnosed with ligneous conjunctivitis and congenital hydrocephalus. They had progressive macrocephaly, which led to the insertion of a ventriculoperitoneal shunt.
View Article and Find Full Text PDFFront Cardiovasc Med
June 2024
Department of Chemistry and Biochemistry and the W.M. Keck Center for Transgene Research, University of Notre Dame, Notre Dame, IN, United States.
Human plasminogen (PLG), the zymogen of the fibrinolytic protease, plasmin, is a polymorphic protein with two widely distributed codominant alleles, PLG/Asp and PLG/Asn. About 15 other missense or non-synonymous single nucleotide polymorphisms (nsSNPs) of PLG show major, yet different, relative abundances in world populations. Although the existence of these relatively abundant allelic variants is generally acknowledged, they are often overlooked or assumed to be non-pathogenic.
View Article and Find Full Text PDFAdv Skin Wound Care
July 2024
Robert Wayne Decker, MD, is Clinical Assistant Professor of Medicine, Cedars-Sinai Medical Center, Los Angeles, California, USA. Joseph Mickler Parker, MD, is Consultant to Kedrion Biopharma Inc, Fort Lee, New Jersey. Jeremy Lorber, MD, is Assistant Clinical Professor, Cedars-Sinai Medical Center. Roberto Crea, DVM, is Medical Affairs Director, Kedrion S.p.A, Barga, Italy. Karen Thibaudeau, PhD, is Medical Affairs Director, Prometic Bioproduction, Laval, Quebec, Canada.
Intravenous plasminogen replacement therapy for patients with plasminogen deficiency type 1 (hypoplasminogenemia) was recently approved for marketing in the US. In this case report, the authors describe a 33-year-old man with hypoplasminogenemia who developed nonhealing postsurgical wounds following trauma to his right hand despite receiving standard treatment for 4 months. The patient was enrolled in a compassionate-use protocol with intravenous plasminogen replacement therapy and experienced prompt resolution of surgical wounds.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!